Cookie-Settings

We use technically necessary cookies for the operation of the website. Other cookies are only set with your consent. We use these to statistically analyse the use of the website (location, time, end device, referrer URL). We also share information about the use of the website with our provider Google LLC. We have also integrated videos into our website via the provider Vimeo, a video hosting platform. The service provider is Vimeo Inc. Both providers may combine this information with other data. Your data may also be transferred to the USA. The USA (and other non-EEA countries) do not offer a level of data protection comparable to the EU; for example, government agencies can access data without any reason. However, both Google LLC. and Vimeo Inc. are committed to data protection-compliant processing with the EU standard contractual clauses.
You can revoke your consent to cookies and data transfer at any time with effect for the future. You can find more information in our privacy policy.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

DE
  • Home
  • About medac
  • Information for patients
  • Healthcare professionals
  • Products
  • Career opportunities
  • Media
  • Trecondi® - the new original from medac

    After 20 years of intensive research and development activity in the field of haematology and oncology, medac received EU-wide marketing authorisation for its new product Trecondi® (treosulfan) on 20 June 2019. medac‘s haematology portfolio is strengthened once again with this innovative therapeutic agent.

    Trecondi® is the first and only product containing treosulfan to have received marketing authorisation in Germany in haematology and therefore offers a new perspective compared with previous therapies.

    medac will begin the official sale of Trecondi® in Germany in August.

    Nach oben